EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer

Giulia Santo, Gianpaolo Di Santo, Anna Sviridenko, Steffen Bayerschmidt, Lukas Wirth, Fabian Scherbauer, Peter Lehmann, Elisabeth von Guggenberg, Clemens Decristoforo, Isabel Heidegger-Pircher, Jasmin Bektic, Irene Virgolini iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06905-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Giulia Santo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical University of Innsbruck, Anichstraße 35, Innsbruck, 6020, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Neoplasm Metastasis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Innsbruck and Medical University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The purpose of this study was to evaluate the safety and outcome of rechallenge [ 177 Lu]Lu-PSMA-I&T in newly progressed mCRPC patients after response to initial [ 177 Lu]Lu-PSMA radioligand therapy (PRLT).

Methods

We retrospectively included 18 patients who underwent rechallenge with [ 177 Lu]Lu-PSMA-I&T. All patients presented with (i) newly progressed disease after response to initial PRLT; (ii) a [ 68 Ga]Ga-PSMA-11 PET/CT confirming the presence of PSMA-positive metastases; iii) ECOG performance status 0–1. Adverse events were graded according to CTCAE v5.0. Response was assessed by PSA and classified according to PCWG3 recommendations. For patients who underwent restaging with [ 68 Ga]Ga-PSMA-11 PET/CT, imaging response was categorised according to adapted PERCIST v1.0. In patients with discordant [ 68 Ga]Ga-PSMA-11 PET/CT and PSA, other available imaging modalities were evaluated to confirm disease status. Overall survival (OS) was calculated from the first cycle of initial PRLT and rechallenge PRLT, respectively, until last patient contact or death.

Results

Patients were initially treated with a median of 5 cycles (range 4–7) and were rechallenged after a median of 9 months (range 3–13). Each patient received a median of 4 (range 2–7) rechallenge cycles (median cumulative activity 26.1 GBq). None of the patients experienced life-threatening G4 adverse events during either treatment period. Grade 3 adverse events included one case of anaemia, one case of thrombocytopenia, and one case of renal failure. In 8/18 patients long-term toxicities were evaluated. Serious toxicities (≥ Grade 3) occurred in 3/8 patients ( n = 1 G4 thrombocytopenia, n = 1 G4 renal failure and n = 1 pancytopenia and G4 renal failure). Best PSA50%-response was observed in 44% of patients and PSA-disease control was confirmed in 56% of patients at the last cycle. Of the 12/18 patients restaged by imaging, 6/12 (50%) patients had disease control (partial response/stable disease), 1/12 had a mixed response, and 5/12 had progression. After a median follow-up time of 25 months (range 14–44), 10 patients had died, 7 were still alive, and one patient was lost at follow-up. The median OS was 29 months (95%CI, 14.3–43.7 months) for the initial treatment and 11 months (95%CI, 8.1–13.8 months) for the first rechallenge course.

Conclusion

More than half of patients benefit from rechallenge PRLT. Our analysis suggests that rechallenge may prolong survival in selected patients, with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumNeoplasm MetastasisHumansMaleAgedMiddle AgedRetrospective StudiesTreatment OutcomeAged, 80 and overRadiopharmaceuticalsPositron Emission Tomography Computed TomographyRadioisotopesSafetyHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Stichwörter der Autor:innen

ProstateRLTRechallenge[177Lu]Lu-PSMA-I&TmCRPC

Substanzen

LutetiumPluvictoRadiopharmaceuticalsRadioisotopesLutetium-177Heterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Medical University of Innsbruck, Anichstraße 35, Innsbruck, 6020, Austria.
  • Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  • Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Nuclear Medicine, Medical University of Innsbruck, Anichstraße 35, Innsbruck, 6020, Austria. irene.virgolini@i-med.ac.at.

ORCID-Profile: Irene Virgolini

Förderung

  • University of Innsbruck and Medical University of Innsbruck

Zitieren

APA

Santo, G., Di Santo, G., Sviridenko, A., Bayerschmidt, S., Wirth, L., Scherbauer, F., Lehmann, P., von Guggenberg, E., Decristoforo, C., Heidegger-Pircher, I., Bektic, J., & Virgolini, I. (2024). Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06905-5

Vancouver

Santo G, Di Santo G, Sviridenko A, Bayerschmidt S, Wirth L, Scherbauer F, et al. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06905-5

BibTeX
@article{Santo2024,
  author = {Santo, Giulia and Di Santo, Gianpaolo and Sviridenko, Anna and Bayerschmidt, Steffen and Wirth, Lukas and Scherbauer, Fabian and Lehmann, Peter and von Guggenberg, Elisabeth and Decristoforo, Clemens and Heidegger-Pircher, Isabel and Bektic, Jasmin and Virgolini, Irene},
  title = {Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06905-5}
}
Kostenlos starten →